PCM
FENC icon

Prelude Capital Management’s Fennec Pharmaceuticals FENC Stock Holding History

Prelude Capital Management’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$182K Buy
+29,599
New +$229K 0.01% 934
2020
Q1 		– Sell
-244
Closed -$2K – 1600
2019
Q4 		$2K Sell
244
-26
-10% -$140 ﹤0.01% 1825
2019
Q3 		$1K Sell
270
-32
-11% -$141 ﹤0.01% 1635
2019
Q2 		$1K Sell
302
-13
-4% -$55 ﹤0.01% 1592
2019
Q1 		$2K Buy
+315
New +$2.07K ﹤0.01% 1678

Other funds holding FENC

RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCM
Potomac Capital Management New York $115M AUM

Prelude Capital Management's FENC Position: Q1 2026 in Review

Prelude Capital Management opened a new position in Fennec Pharmaceuticals (FENC) in Q1 2026: 29,599 shares worth $182K. The stake represents 0.01% of the portfolio and ranks #934 among its holdings. This is a return to the name: Prelude Capital Management previously reported a position in FENC as recently as Q4 2019.

Prelude Capital Management first reported a position in FENC in Q1 2019 and has held it in 5 quarters since. 90 funds tracked by Wall St. Rank hold FENC as of Q1 2026.

  • Prelude Capital Management held 29,599 shares of Fennec Pharmaceuticals worth $182K as of Q1 2026.
  • Fennec Pharmaceuticals was a new Prelude Capital Management position in Q1 2026.
  • Fennec Pharmaceuticals made up 0.01% of Prelude Capital Management's portfolio in Q1 2026, its #934 holding.
  • Prelude Capital Management first reported a position in Fennec Pharmaceuticals in Q1 2019 and has held it in 5 quarters since.
  • 90 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.